The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Francesco Caponigro

Medical Oncology A

National Tumor Institute G. Pascale

Napoli

Italy

[email]@sirio-oncology.it

Name/email consistency: medium

 
 
 
 
 
 
 

Affiliations

  • Medical Oncology A, National Tumor Institute G. Pascale, Napoli, Italy. 2000 - 2002
  • EORTC Early Clinical Studies Group, New Drug Development Program, Brussels, Belgium. 2002
  • National Tumor Institute of Naples Fondazione G Pascale, Via M Semmola, 80131 Napoli, Italy. 2002
  • National Tumor Institute of Naples, Italy. 2000 - 2001
  • Southern Italy Cooperative Oncology Group, c/o National Tumor Institute of Naples, Via M Semmola, 80131 Napoli, Italy. 2001
  • Divisione Oncologia Medica A, Istituto Nazionale Tumori Napoli, Italy. 1999

References

  1. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Caponigro, F., Dittrich, C., Sorensen, J.B., Schellens, J.H., Duffaud, F., Paz Ares, L., Lacombe, D., de Balincourt, C., Fumoleau, P. Eur. J. Cancer (2002) [Pubmed]
  2. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. Caponigro, F., Rosati, G., De Rosa, P., Avallone, A., De Rosa, V., De Lucia, L., Comella, P., Comella, G. Oncology (2002) [Pubmed]
  3. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Caponigro, F. Anticancer. Drugs (2002) [Pubmed]
  4. Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. Caponigro, F., Avallone, A., Rivellini, F., Comella, P., Ionna, F., De Rosa, V., Comella, G. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  5. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Caponigro, F., Massa, E., Manzione, L., Rosati, G., Biglietto, M., De Lucia, L., Sguotti, C., Sganga, P., Avallone, A., Comella, P., Mantovani, G., Comella, G. Ann. Oncol. (2001) [Pubmed]
  6. Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. Caponigro, F., Avallone, A., Budillon, A., Comella, P., Comella, G. Anticancer. Drugs (2001) [Pubmed]
  7. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Caponigro, F., Comella, P., Budillon, A., Bryce, J., Avallone, A., De Rosa, V., Ionna, F., Comella, G. Ann. Oncol. (2000) [Pubmed]
  8. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG). Caponigro, F., Comella, P., Rivellini, F., Avallone, A., Budillon, A., Di Gennaro, E., Mozzillo, N., Ionna, F., De Rosa, V., Manzione, L., Comella, G. Ann. Oncol. (2000) [Pubmed]
  9. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. Caponigro, F., Avallone, A., McLeod, H., Cartenì, G., De Vita, F., Casaretti, R., Morsman, J., Blackie, R., Budillon, A., De Lucia, L., Gravina, A., Catalano, G., Comella, P., Comella, G. Clin. Cancer Res. (1999) [Pubmed]
 
WikiGenes - Universities